Ulipristal

Drug Profile

Ulipristal

Alternative Names: CDB-2914; ella; ellaOne; Esmya; Fibristal; HRP 2000; PGL-4001; RTI 3021-12; RU 44675; Ulipristal acetate; UPA; UPA C-IUS; UPA C-ring; UPA-IUS; UPA-UF; UPA-VR; VA-2914

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator HRA Pharma; National Institutes of Health (USA)
  • Developer Allergan; ASKA Pharmaceutical; HRA Pharma; Population Council (USA); PregLem
  • Class Norpregnadienes; Oral contraceptives; Small molecules
  • Mechanism of Action Selective progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Female genital diseases; Uterine leiomyoma

Highest Development Phases

  • Marketed Pregnancy; Uterine leiomyoma
  • Discontinued Breast cancer; Endometriosis; Menopausal syndrome

Most Recent Events

  • 17 Jan 2017 Efficacy and adverse events data from the phase III VENUS II trial in Uterine leiomyoma released by Allergan and Gedeon Richter
  • 21 Nov 2016 Health Canada approves ulipristal 5mg for intermittent treatment in the long-term management of uterine fibroids
  • 11 May 2016 Launched for Pregnancy (Prevention) in Croatia, Tunisia, Bosnia-Herzegovina, Serbia (PO) before 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top